J Cancer 2017; 8(7):1255-1262. doi:10.7150/jca.16450 This issue Cite

Research Paper

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development

JS Berry1✉, TJ Vreeland2, DF Hale1, DO Jackson3, AF Trappey3, JM Greene3, MO Hardin4, GS Herbert3, GT Clifton5, GE Peoples6✉

1. Department of Surgery, Division of Colon and Rectal Surgery, Washington University, St. Louis, MO;
2. Department of Surgery, Womack Army Medical Center, Fort Bragg, NC;
3. Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX;
4. Department of Surgery, Madigan Army Medical Center, Fort Lewis, WA;
5. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX;
6. Cancer Vaccine Development Program, San Antonio, TX and Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD.

Citation:
Berry JS, Vreeland TJ, Hale DF, Jackson DO, Trappey AF, Greene JM, Hardin MO, Herbert GS, Clifton GT, Peoples GE. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development. J Cancer 2017; 8(7):1255-1262. doi:10.7150/jca.16450. https://www.jcancer.org/v08p1255.htm
Other styles

File import instruction

Abstract

INTRODUCTION: Peptide vaccines offer anti-tumor efficacy with very low toxicity. However, repeat stimulation with an immunogenic peptide leads to activation induced cell death (AICD), decreasing efficacy. We engineered variants of an immunogenic peptide (E39) and tested their ability to induce a robust, sustainable immune response.

METHODS: Multiple variants of E39 were created by exchanging 1 or 2 amino acids. We tested the PBMC proliferation, cytokine production and cytolytic activity induced by each variant peptide. RESULTS: Repeated stimulation with E39 likely led to in vitro AICD, while stimulation with E39' led to T-cell proliferation with less evidence of AICD, modest cytokine production and high CTL activity. CONCLUSIONS: E39' appears to be the optimal variant of E39 for inducing effective long-term immunity.

Keywords: Folate binding protein, folate receptor alpha, J65, E39, E39'.


Citation styles

APA
Berry, JS., Vreeland, TJ., Hale, DF., Jackson, DO., Trappey, AF., Greene, JM., Hardin, MO., Herbert, GS., Clifton, GT., Peoples, GE. (2017). Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development. Journal of Cancer, 8(7), 1255-1262. https://doi.org/10.7150/jca.16450.

ACS
Berry, JS.; Vreeland, TJ.; Hale, DF.; Jackson, DO.; Trappey, AF.; Greene, JM.; Hardin, MO.; Herbert, GS.; Clifton, GT.; Peoples, GE. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development. J. Cancer 2017, 8 (7), 1255-1262. DOI: 10.7150/jca.16450.

NLM
Berry JS, Vreeland TJ, Hale DF, Jackson DO, Trappey AF, Greene JM, Hardin MO, Herbert GS, Clifton GT, Peoples GE. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development. J Cancer 2017; 8(7):1255-1262. doi:10.7150/jca.16450. https://www.jcancer.org/v08p1255.htm

CSE
Berry JS, Vreeland TJ, Hale DF, Jackson DO, Trappey AF, Greene JM, Hardin MO, Herbert GS, Clifton GT, Peoples GE. 2017. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development. J Cancer. 8(7):1255-1262.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image